Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
Liu X., Munro AP., Feng S., Janani L., Aley PK., Babbage G., Baxter D., Bula M., Cathie K., Chatterjee K., Dejnirattisai W., Dodd K., Enever Y., Qureshi E., Goodman AL., Green CA., Harndahl L., Haughney J., Hicks A., van der Klaauw AA., Kwok J., Libri V., Llewelyn MJ., McGregor AC., Minassian AM., Moore P., Mughal M., Mujadidi YF., Holliday K., Osanlou O., Osanlou R., Owens DR., Pacurar M., Palfreeman A., Pan D., Rampling T., Regan K., Saich S., Serafimova T., Saralaya D., Screaton GR., Sharma S., Sheridan R., Sturdy A., Supasa P., Thomson EC., Todd S., Twelves C., Read RC.
The authors regret that there has been an error published within Fig. 5 of this article. The authors inadvertently pasted the anti-spike plots for the “≥70 years” group instead of the pseudo-neutralising antibody plots (pages 808–809) to Fig. 5A and B. These plots replicate the “≥70 years” group in Fig. 4A and B on pages 806–807. The authors have confirmed that the error does not affect the interpretation of the results and the rest of the paper, and the plots for the “<70 years” group in Fig. 5 are correct. The revised Fig. 5 contains the correct plots for pseudo-neutralising antibody data has now been updated in the original publication. The authors would like to apologise for any inconvenience caused.